EMEA-002962-PIP01-21
Key facts
| Active substance |
AZD8233 sodium, PCSK9-targeted, antisense oligonucleotide (ASO)
|
| Therapeutic area |
Cardiovascular diseases
|
| Decision number |
P/0465/2021
|
| PIP number |
EMEA-002962-PIP01-21
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
AstraZeneca AB
E-mail: paediatrics@astrazeneca.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|